PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR

Ibrutinib, an FDA approved, orally administered BTK inhibitor, has demonstrated high response rates to diffuse large B-cell lymphoma (DLBCL), however, complete responses are infrequent and acquired resistance to BTK inhibition can emerge. The present study investigated the role of the platelet-deriv...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Jia, Wang, Leiping, Tao, Zhonghua, Zhang, Jian, Lv, Fangfang, Cao, Junning, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115192/
https://www.ncbi.nlm.nih.gov/pubmed/32186759
http://dx.doi.org/10.3892/mmr.2020.11022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115192/
https://www.ncbi.nlm.nih.gov/pubmed/32186759
http://dx.doi.org/10.3892/mmr.2020.11022

Ejemplares similares